New peer-reviewed publication confirms accuracy and clinical utility of PainChek® in residents in aged care living with moderate to severe dementia
• New study published in the Journal of Pain Research on electronic pain assessment tool PainChek® (formerly known as ePAT) confirms its accuracy.
• PainChek® - a point of care solution that uses automated facial analysis to help evaluate the presence of pain - demonstrated excellent performance with high sensitivity (96.1%), high specificity (91.4%) and high clinical accuracy (95.0%).
• High scores for clinical usefulness of the new technology (95.0%) demonstrates its value in the clinical setting to clinicians and carers.
A third peer reviewed study has been published in the Journal of Pain Research which supports the clinical usefulness of PainChek®. In order to attract widespread clinical use, it is important to confirm both the accuracy and usefulness of the technology compared to existing methods for assessing pain. Clinicians will naturally ask themselves "Does the new tool work and is it as good as what we already use?"
PainChek Ltd CEO Philip Daffas said "These results, combined with previous studies, support the clinical usefulness of PainChek® and further confirms its accuracy in detecting and quantifying pain in non-verbal people, such as those with advanced dementia. The findings also provide clinicians with great confidence for wider uptake of the tool in clinical practice in Australia and internationally".
PCK Price at posting:
5.4¢ Sentiment: Hold Disclosure: Held
